Following Priority Review, the U.S. FDA granted HYRNUO® (sevabertinib) approval for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) ...

Currently there are sever global static variables that can make using libsrtp from multiple sub projects problematic. All non const variables should be removed. Current known ones include ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Hernexeos for adults with unresectable or metastatic HER2-mutant NSCLC. It received accelerated ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Packaged as part of the 2018 version 10 release, the Java var reserved word introduced type ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

Dr Jonathan Goldman, of the University of California, Los Angeles, shares key updates in metastatic non-small cell lung cancer from ASCO 2025. Dr Goldman reviews findings from TROPION-Lung02, which ...

ABSTRACT: Security vulnerabilities are a widespread and costly aspect of software engineering. Although tools exist to detect these vulnerabilities, non-machine learning techniques are often rigid and ...

Neoadjuvant TKI therapy in non-metastatic GIST patients can reduce surgical complexity, with CE-CT imaging predicting benefits in 22 of 39 patients. Significant tumor volume reduction was observed ...

Introduction Ischaemia–reperfusion (I/R) injury remains a major challenge in heart transplantation, with mortality risk increasing significantly when allograft ischaemic time exceeds 4 hours.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BBO-8520 for the treatment of adult patients with previously treated, KRAS G12C-mutated metastatic non-small cell lung ...